2016 | 2015 | 2014 | 2013
DateTitle 
December 14, 2015Incyte to Present at the 34th Annual J. P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 14, 2015-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 34th Annual J. P. Morgan Healthcare Conference on Monday, January 11, 2016 at 1:30 p.m. PST (4:30 p.m. EST) in San Francisco. The presentation will be webcast live and can be accessed within the Investors section of www.incyte.com under Events and Presentations. Investors interested in listening to the live webcas... 
Printer Friendly Version
December 05, 2015Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint
Patients with polycythemia vera without enlarged spleen treated with Jakafi achieved hematocrit control without phlebotomy WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2015-- Incyte Corporation (Nasdaq:INCY) announces the Phase 3 RESPONSE-2 study of Jakafi® (ruxolitinib) met its primary endpoint. Treatment with Jakafi achieved hematocrit control without the need for phlebotomy in patients with inadequately controlled polycythemia vera (PV) resi... 
Printer Friendly Version
December 05, 2015Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi® (ruxolitinib) in Patients with Myeloproliferative Neoplasms (MPNs)
COMFORT-II data demonstrate that patients with myelofibrosis treated with Jakafi achieved a 33 percent reduction in the risk of death after five years WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 5, 2015-- Incyte Corporation (Nasdaq:INCY) announces data from two Phase 3 studies evaluating the long-term safety and efficacy of Jakafi® (ruxolitinib) in patients with Myeloproliferative Neoplasms (MPNs). In myelofibrosis (MF), results of a five-year fol... 
Printer Friendly Version
November 30, 2015Incyte’s Jakafi® (ruxolitinib) to be Featured in over 60 Abstracts at ASH Annual Meeting
Five-year COMFORT-II data in myelofibrosis and multiple ruxolitinib combination studies in MPNs and other hematologic malignancies accepted as oral and poster presentations WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 30, 2015-- Incyte Corporation (Nasdaq:INCY) announces that more than 60 abstracts featuring data from its ongoing clinical development program for Jakafi® (ruxolitinib) will be presented at the upcoming American Society of Hematology ... 
Printer Friendly Version
November 07, 2015Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate
INDIANAPOLIS, Nov. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monotherapy in helping patients achieve clinical remission. Findings will be shared at the American College of Rheumatology /Association of Rheumatology Health Professionals annual meeting in San Francisco, reveali... 
Printer Friendly Version
November 07, 2015Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis
Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab Detailed results from pivotal phase 3 study RA-BEAM presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting PR Newswire, Indianapolis, November 7, 2015 Eli Lilly and... 
Printer Friendly Version
November 03, 2015Epacadostat in Combination with Pembrolizumab Demonstrates Promising Clinical Activity in Multiple Advanced Cancers
Combination of IDO1 inhibitor plus PD-1 antagonist demonstrates responses and disease control in a broad range of tumor types and is generally well-tolerated with low rates of Grade 3 or higher adverse events WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 3, 2015-- Incyte Corporation (Nasdaq:INCY) announces the first presentation of findings from the ongoing proof-of-concept Phase 1/2 study evaluating epacadostat, Incyte’s selective IDO1 inhibitor, i... 
Printer Friendly Version
November 03, 2015Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
- $161 million of 2015 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 65 percent growth over the same period last year - Positive results from two pivotal trials of baricitinib to be highlighted at ACR; baricitinib superior to both methotrexate (RA-BEGIN) and to Humira® (adalimumab) (RA-BEAM) in reducing the signs and symptoms of rheumatoid arthritis - Agreement announced with Merck to expand clinical c... 
Printer Friendly Version
October 14, 2015Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
INDIANAPOLIS, Oct. 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis. The study met its primary objective of demonstrating superiority compared to placebo after 12 weeks of treatment based on ACR20 response – a standard clinical measure that repre... 
Printer Friendly Version
October 13, 2015Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 13, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, November 3, 2015. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
October 13, 2015Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Oct. 13, 2015-- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical collaboration to include a Phase 3 study evaluat... 
Printer Friendly Version
October 02, 2015Data at SITC Annual Meeting to Highlight Progress of Incyte’s Immuno-oncology Portfolio
Results of a proof-of-concept study of epacadostat, Incyte’s IDO1 inhibitor, in combination with pembrolizumab to be presented as a late-breaking abstract WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 2, 2015-- Incyte Corporation (Nasdaq:INCY) announces that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs... 
Printer Friendly Version
September 29, 2015Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis
INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response ra... 
Printer Friendly Version
September 15, 2015Incyte to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 15, 2015-- Incyte Corporation (Nasdaq: INCY) announced today it will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. Investors interested in listening to the live webcast should log on before th... 
Printer Friendly Version
September 10, 2015MPN Awareness Day Raises Awareness and Support for the Nearly 300,000 People in the United States Affected by Rare Blood Cancers
September 10, 2015, commemorates the third annual MPN Awareness Day Incyte supports MPN awareness by providing patient resources and programs throughout September Call for MPN Heroes™ Recognition Program Nominations Ends Today WILMINGTON, Del.--(BUSINESS WIRE)--September is Blood Cancer Awareness Month and, today, the MPN Coalition, a group of seven patient advocacy organizations, recognizes MPN Awareness Day. MPN Awareness Day, September 10... 
Printer Friendly Version
September 02, 2015Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody
Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 2, 2015-- Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the exclusive developme... 
Printer Friendly Version
September 01, 2015Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 1, 2015-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of September: Morgan Stanley 2015 Global Healthcare Conference on Thursday, September 17, 2015 at 12:20 pm (EDT) in New York; and Bank of America Merrill Lynch Global Healthcare Conference 2015 on Thursday, September 17, 2015 at 1:45 pm (BST) in Lo... 
Printer Friendly Version
August 21, 2015Incyte Named 7th Most Innovative Company in the World by Forbes Magazine
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 21, 2015-- Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, today announced it has been ranked 7th on Forbes magazine’s 2015 list of the World’s Most Innovative Companies. Forbes’ ranking is based on the companies’ “innovation premium”, and only includes industries that are known to inves... 
Printer Friendly Version
August 04, 2015Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$142 million of 2015 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 69 percent growth over the same period last year 2015 guidance for Jakafi net product revenues increased to range of $560 million to $575 million, driven by strong underlying demand Positive results from two pivotal trials of baricitinib in rheumatoid arthritis presented at EULAR Multiple a... 
Printer Friendly Version
July 14, 2015Incyte to Report Second Quarter Financial Results on August 4
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 4, 2015. The schedule for the press release and conference call/webcast is as follows:         ... 
Printer Friendly Version
July 07, 2015Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
Agreement to collaborate on basic and translational research to enable novel therapeutic approaches for patients with cancer Incyte to provide financial support for the grant-based research program, which has an initial collaboration period of three years, with the option to extend WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 7, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it has entered into... 
Printer Friendly Version
June 19, 2015Incyte Announces Organizational and Management Changes to Drive Future Global Expansion
Jim Daly, EVP and Chief Commercial Officer, to leave Incyte at end of June, for personal reasons Dr. Barry Flannelly, appointed EVP and General Manager U.S., to lead regional operating team for United States Incyte to establish Global Product Strategy and BD&L unit to strategically manage growing portfolio WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 19, 2015-- Incyte Corporation (Nasdaq: INCY) ... 
Printer Friendly Version
June 10, 2015Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
EULAR congress in Rome will be first public presentations of Phase 3 data INDIANAPOLIS, June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte prev... 
Printer Friendly Version
May 28, 2015Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will be presented on June 11 during the Scientific Programme for the EULAR Congress 2015 in Rome, Italy. The webcast will be held from 10:00 to11:00 a.m. Eastern Daylight Time. The live audio webcast... 
Printer Friendly Version
May 27, 2015Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings
Results from ongoing proof-of-concept trial of PI3Kδ inhibitor INCB40093 as monotherapy and in combination with JAK1 inhibitor INCB39110 in B-cell malignancies, including Hodgkin lymphoma Follow-up results from pivotal RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, showing 83% of patients were still receiving ruxolitinib at a median exposure of 111 weeks WILMINGTON, Del.--(BUSINESS WIR... 
Printer Friendly Version
April 30, 2015Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$115 million of 2015 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 66 percent growth over the same period last year $25 million milestone received from Novartis related to the approval of Jakavi® (ruxolitinib) for polycythemia vera in Europe; $16 million product royalties from sales of Jakavi, representing 60 percent growth over the same period last year Primary e... 
Printer Friendly Version
April 23, 2015Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 23, 2015-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of May: Deutsche Bank Securities 40th Annual Health Care Conference on Thursday, May 7, 2015 at 10:00 am (EDT) in Boston; Bank of America Merrill Lynch 2015 Health Care Conference on Thursday, May 14, 2015 at 8:00 am (PDT) in Las Vegas; and ... 
Printer Friendly Version
April 17, 2015Incyte’s Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting
Live discussion, presentation and webcast to be held on April 20th Incyte's FGFR, BRD and PIM inhibitor programs described Clinical trials of FGFR inhibitor underway; BRD inhibitor expected to enter clinical development during second quarter 2015 Immuno-therapeutic activity of JAK and PI3Kδ inhibitors highlighted Potential for combination strategies within and across both targete... 
Printer Friendly Version
April 14, 2015Incyte to Report First Quarter Financial Results on April 30
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2015 financial results conference call for 8:00 a.m. ET on Thursday, April 30, 2015. The schedule for the press release and conference call is as follows:           ... 
Printer Friendly Version
April 14, 2015Incyte to Establish European Headquarters in Geneva, Switzerland
New facility to serve as European base for Incyte’s drug development operations Location provides efficient access to key clinical trial experts and institutions WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2015-- Incyte Corporation (Nasdaq:INCY) today announced that it will establish the new headquarters of Incyte Europe S.a.r.l (“Incyte Europe”) in Geneva, Switzerland. Incyte intends to use Incyte Europe as the b... 
Printer Friendly Version
March 17, 2015Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that Novartis received approval from the European Commission for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and L... 
Printer Friendly Version
March 02, 2015Incyte Appoints Steven H. Stein, MD as Chief Medical Officer
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’s extensive oncology portfolio. Steve... 
Printer Friendly Version
February 26, 2015Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera – a Rare, Progressive Blood Cancer
Results expected to provide better strategies for both patients and physicians to manage the burden of this disease WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 26, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it is sponsoring the first major observational study of patients living with polycythemia vera (PV) in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, ... 
Printer Friendly Version
February 23, 2015Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study
INDIANAPOLIS, Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional ... 
Printer Friendly Version
February 17, 2015Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 17, 2015-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March: Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 10:40 am (EST) in Boston; and Barclays Global Healthcare Conference on Wednesday, March 11, 2015 at 3:50 pm (EDT) in Miami The prese... 
Printer Friendly Version
February 12, 2015Incyte Reports 2014 Fourth-Quarter and Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders on Key Clinical Programs
$106 million of 2014 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 46 percent growth over the same period last year $358 million of 2014 full-year net product revenues from Jakafi, representing 52 percent growth over last year 2015 guidance for Jakafi net product revenues in the range of $525 million to $565 million, reflecting continued growth in underlying demand in mye... 
Printer Friendly Version
January 28, 2015Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
Data show Jakafi® (ruxolitinib) was superior to standard therapy; resulting in durable hematocrit control, spleen volume reduction and complete hematological remission in patients with uncontrolled polycythemia vera (PV)1 PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack2 Jakafi® was recently appr... 
Printer Friendly Version
January 27, 2015Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2015-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, February 12, 2015. The schedule for the press release and conference call is as follows:         ... 
Printer Friendly Version
January 23, 2015Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2015-- Incyte Corporation (Nasdaq: INCY) today announced that it has earned a $25 million milestone payment from Novartis. This payment was triggered by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopting a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyu... 
Printer Friendly Version
January 09, 2015Incyte Board Appoints Two New Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 9, 2015-- Incyte Corporation (Nasdaq: INCY) today announced the appointment of Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin Pharmaceutical Inc., and Paul J. Clancy, Executive Vice President, Finance and Chief Financial Officer of Biogen Idec Inc., as new Directors. The appointments are effective January 20, 2015. “The Incyte board welcomes Jean-Jacques and Paul as their extensive and re... 
Printer Friendly Version
January 09, 2015Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies Agenus to receive $60 million comprised of a $25 million technology and program access fee under the collaboration plus $35 million equity investment in Agenus at $4.51/share Agenus eligible to receive up to $350 million in development, regulatory and commercial... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet